Biopharma venture financing declines 20.2% YOY in Q1 2025 amid persistent investor caution
Biopharmaceutical drug company venture financing witnessed a downturn in Q1 2025, with $6.5bn raised—a 20.2% decline from the $8.1bn raised…
Analyst Comment
Impending US tariffs signal uncertain future for global pharma, says GlobalData
US tariffs likely to disrupt drug development costs and prices, says GlobalData
Top 20 biopharmas’ market cap rises 6% in Q1 2025 amid tariff headwinds
Synthetic hormones and the future of contraception
First two medicinal products to undergo EU joint clinical assessments announced
The 7MM atopic dermatitis market to experience growth, reaching $22.4bn by 2033
Do in vivo CAR-T cell therapies have the potential to overtake ex vivo CAR-Ts?
